• Department of Thoracic Surgery, Gaozhou People’s Hospital, Maoming, 525200, Guangdong, P. R. China;
LIN Wanli, Email: qgw752@163.com
Export PDF Favorites Scan Get Citation

Autologous blood patch pleurodesis (ABPP) was first proposed in 1987. Now it is mainly used to treat intractable pneumothorax and persistent air leakage after pneumonectomy, and also used to treat pneumothorax in children and other rare secondary pneumothorax. Persistent air leakage and pneumothorax of various causes are essentially alveolar pleural fistula. It can usually be treated by closed thoracic drainage, continuous negative pressure suction and surgery. Pleurodesis is a safe and effective alternative to surgery for patients who have failed conventional conservative treatment and can not receive operations. Compared with other pleurodesis adhesives, autologous blood (ABPP) is safer and more effective, and it is simple, painless, cheap and easy to be accepted by patients. But in the domestic and foreign researches in recent years, many details of ABPP treatment have not been standardized. For further research and popularization of ABPP, this article reviews the detailed regulations, efficacy and safety of this technology.

Citation: HUANG Jiawei, LIANG Hanping, XIE Xihao, LIN Wanli. Research progress on autologous blood patch pleurodesis. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2025, 32(1): 136-140. doi: 10.7507/1007-4848.202302003 Copy

Copyright © the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved

  • Previous Article

    The role of circulating inflammatory cytokines in cardiopulmonary bypass-related organs injuries and the treatments
  • Next Article

    Interpretation of 2024 ESC guidelines for the management of peripheral arterial and aortic diseases